Press releases 2022

 

 

ADDvise signs Letter of Intent to acquire CliniChain Holding B.V.

Regulatory press release

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of CliniChain Holding B.V. (”CliniChain”) regarding an acquisition of 100 percent of the shares in CliniChain. CliniChain is a fast-growing international medtech equipment provider for clinical studies. The company offers tailored rental and purchase solutions of medtech equipment that are adapted to…

Read more

ADDvise receives order worth USD 640,000

Regulatory press release

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Hortman Health Care Investment LLC, an investment company in the private healthcare sector, based in the United Arab Emirates. The order is worth approximately USD 640,000 and involves design, supply, and installation of a stem cell laboratory for a clinic in Dubai, United…

Read more

Interim report January 1 – June 30, 2022

Regulatory press release

April-June 2022 Orders received for the period was SEK 260.9 million (122.8), an increase of 112.5 %. Organic growth was 22.3 %. Net revenue for the period was SEK 231.9 million (117.6), an increase of 97.1 %. Organic growth was 3.1 %. Adjusted EBITDA for the period was SEK 31.8 million (15.5) EBITDA for the…

Read more

ADDvise receives allocation decision worth approximately EUR 2.4 million

Regulatory press release

ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from Helsinki University Hospital in Finland regarding digital x-ray equipment with a total value of approximately EUR 2.4 million. Installations are expected to take place during the year 2022 and 2023. In accordance with Finnish procurement law the allocation decision can be appealed…

Read more

ADDvise receives order from Cadwell Industries worth approximately USD 1.7 million

Regulatory press release

ADDvise Group AB’s subsidiary Merit Cables Inc has received an order from Cadwell Industries, a company specialized in electrodes, consumables, supplies, and accessories for neurology, worth approximately USD 1.7 million. The order involves wires for electrodiagnostic supplies such as EEG, EMG and ultrasound for measuring and evaluating electrical brain and muscle activity. Delivery of the…

Read more

ADDvise acquires Seebreath AB

Regulatory press release

ADDvise Group AB has today entered into a share purchase agreement with the owners of Seebreath AB (“Seebreath”) regarding the acquisition of all the outstanding shares of Seebreath. The acquisition is in line with the letter of intent communicated via a press release dated February 28, 2022. Closing of the acquisition takes place today. Seebreath’s…

Read more

Interim report January 1 – March 31 2022

Regulatory press release

January-March 2022 Net revenue for the period was SEK 162.4 million (87.7), an increase of 85.1 %. Organic growth was 4.2 %. Adjusted EBITDA for the period was SEK 21.3 million (8.0) EBITDA for the period was SEK 21.2 million (8.9) Adjusted profit/loss for the period was SEK 5.8 million (1.6) Basic earnings per share…

Read more

ADDvise acquires Surplus Diabetics, Inc.

Regulatory press release

ADDvise Group AB has today entered into a share purchase agreement with the owners of Surplus Diabetics, Inc. (“Surplus Diabetics”) regarding the acquisition of all the outstanding shares of Surplus Diabetics in accordance with the letter of intent communicated via a press release dated January 17, 2022. Closing of the acquisition takes place today. Surplus…

Read more

ADDvise Group publishes the annual report 2021

Regulatory press release

Today, April 14, 2022, ADDvise Group AB (publ) is publishing its annual report for 2021. The annual report is available on ADDvise’s website: www.addvisegroup.se. The annual report is published in Swedish and English. The Swedish version represents the original. For further information, please contact: Rikard Akhtarzand, CEO +46765-25 90 71 rikard.akhtarzand@addvisegroup.se Sebastian Robson, CFO +46…

Read more

ADDvise Group raises its EBITDA target for 2022

Regulatory press release

In the light of the company’s continued progress, the Board of Directors of ADDvise Group have decided to raise the 2022 EBITDA target from the previous target communicated on 23 September 2021. For the financial year 2022, rolling 12 months pro forma basis, ADDvise expects to reach an EBITDA result of at least SEK 200…

Read more

Notice convening the Annual General Meeting of ADDvise Group AB (publ)

Regulatory press release

ADDvise Group AB (publ), reg. no. 556363–2115 (the "Company" and "ADDvise"), hereby convenes the annual general meeting to be held on Friday 6 May 2022 at 10.00 a.m. at Grev Turegatan 30 in Stockholm. Registration for the meeting will begin at 09.30 a.m. Registration and notification Shareholders wishing to attend the annual general meeting must:…

Read more

ADDvise receives order from SHCS on vital signs monitoring solution worth approximately USD 2 million

Regulatory press release

ADDvise Group AB’s subsidiary Southern Life Systems Inc (“SLS”) has signed a one-year term agreement with Signature Healthcare Consulting Services, LLC (“SHCS”), a group providing personalized medical services in primary care, specialty care and hospital care. The agreement regards an order of Rosie Connectivity Solution, system for vital signs monitoring, in 110 nursing homes in…

Read more

ADDvise Group completes a directed new share issue of approximately SEK 100 million which was oversubscribed

Regulatory press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER…

Read more

ADDvise Group announces intention to carry out a directed new share issue of approximately SEK 100 million

Regulatory press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER…

Read more

ADDvise receives allocation decision worth approximately SEK 44 million

Regulatory press release

ADDvise Group AB (publ)’s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm-Gotland worth approximately SEK 44 million. The allocation decision consists of delivery of blood specimen collection equipment during a four-year period starting May 2022. The allocation decision is subject to an appeal time expiring 18 March 2022. For further information,…

Read more

ADDvise acquires JTECH Medical

Regulatory press release

ADDvise Group AB has today entered into a share purchase agreement with the owner of JTECH Medical (“JTECH”) regarding the acquisition of all shares of the company in accordance with the letter of intent communicated via a press release dated December 22, 2021. Closing of the acquisition takes place today. JTECH’s revenue for 2021 amounted…

Read more

ADDvise signs Letter of Intent to acquire Seebreath AB

Regulatory press release

ADDvise signs Letter of Intent to acquire Seebreath AB ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Seebreath AB (”Seebreath”) regarding an acquisition of 100 percent of the shares in Seebreath. Seebreath is a Swedish medtech company developing and producing colorimetric CO2-indicating products used in respiratory care. The products are…

Read more

Year-end report 2021, January 1 – December 31

Regulatory press release

October – December 2021 Net revenue for the period was SEK 155.0 million (96.8), an increase of 60.1 %. Organic growth was 12.8 %. Adjusted EBITDA for the period was SEK 19.0 million (12.6) EBITDA for the period was SEK 19.4 million (16.3) Adjusted profit/loss for the period was SEK 3.8 million (2.4) Basic earnings…

Read more

ADDvise acquires Poly Pharmaceuticals, Inc.

Regulatory press release

ADDvise Group AB has today entered into a share purchase agreement with the shareholders of Poly Pharmaceuticals, Inc. (“Poly Pharma”) regarding the acquisition of all the outstanding shares of Poly Pharma in accordance with the letter of intent communicated via a press release dated October 21, 2021. Closing of the acquisition will take place during…

Read more

The nomination committee’s proposal of board of directors in ADDvise Group AB (publ)

Regulatory press release

To the annual general Meeting (AGM) of ADDvise Group AB (publ) on 6 May 2022, the nomination committee has decided to propose re-election of Fredrik Celsing, Staffan Torstensson, Erland Pontusson and Johanne Brændgaard as members of the board of directors. In addition, the nomination committee proposes the election of Anna Ljung. It is proposed that…

Read more

ADDvise signs Letter of Intent to acquire Surplus Diabetic, Inc.

Regulatory press release

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Surplus Diabetic, Inc. (”Surplus Diabetic”) regarding an acquisition of 100 percent of the shares in Surplus Diabetic. Surplus Diabetic is an American medtech company, specialized in supplying the U.S. market with diabetes products, such as glucose monitors, insulin and test stripes.…

Read more

Bondholders approve amendment to bond terms and conditions

Regulatory press release

ADDvise Group AB (publ) (the "Company") today announces the successful completion of the written procedure that was initiated on 16 December 2021 (the "Written Procedure") in relation to the Company's outstanding up to SEK 500,000,000 senior secured bonds with ISIN SE0015222088 (the "Bonds"), that sought approval from bondholders ("Bondholders") for certain amendments to the terms…

Read more

Major shareholder issues call options to board members, senior executives and certain other employees in ADDvise Group

Non-regulatory press release

The board of directors of ADDvise Group AB has today been informed that one of its major shareholders, Per Åhlgren through GoMobile nu Aktiebolag, has issued call options in ADDvise Group AB to board members, senior executives and certain other employees in ADDvise Group. In total, 3,696,666 call options have been issued to eleven persons.…

Read more

ADDvise receives order worth USD 1.1 million

Regulatory press release

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Design Infinity LCC, a Dubai based pharmaceutical industry engineering, interior design and fit out contractor. The order is worth approximately USD 1.1 million and involves design, supply, and installation of a 1000 sqm cleanroom facility for pharmaceutical production by the Himalaya Drug Company…

Read more